Q3 2025
Released Nov 4, 2025, before the open
10-Q filed Nov 4, 2025, 37 days after period end · 0000078003-25-000150
Q3 2025 · 10-Q
Revenue$16.65B$16.65B −5.9% vs Q3 2024+13.7% vs Q2 2025
Net Income$3.54B$3.54B −20.7% vs Q3 2024+21.7% vs Q2 2025
EPS Diluted$0.62$0.62 −20.5% vs Q3 2024+21.6% vs Q2 2025
Operating Cash Flowderived$4,603,000,000−31.4%
Free Cash Flowderived$4,001,000,000−34.0%
Margins · derived
Net margin21.3%−4.0 pt vs Q3 2024
What the release said
The release
Same quarter
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | $16.65B | $17.70B | $13.49B | $22.64B |
| Net Income | $3.54B | $4.47B | -$2.38B | $8.61B |
| EPS Diluted | $0.62 | $0.78 | -$0.42 | $1.51 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pfizer Inc · CIK 78003 · Engraved from SEC EDGAR